Package Leaflet: Information for the Patient.
Okidol25 mg granules
ketoprofen
Read the package leaflet carefully before starting to take this medication, as it contains important information for you.
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist.
Contents of the Package Leaflet
The active ingredient of this medication is ketoprofen lysine salt, which belongs to a group of medications called "Non-steroidal anti-inflammatory drugs" (NSAIDs). These medications provide short-term relief by changing the body's response to pain, inflammation, and fever. Ketoprofen lysine salt is a salt of ketoprofen that the body absorbs quickly and completely.
Okidol is indicated in adults 18 years and older, for the symptomatic relief of occasional mild to moderate pain, such as muscle and joint pain, headache, pain associated with throat irritation, toothache, and menstrual pain, as well as in febrile states.
You should consult a doctor if your condition worsens or does not improve after 3 days of fever and after 5 days of pain.
Do not take Okidol:
active peptic ulcer
ulcers in the stomach or intestines
intestinal bleeding
holes in the stomach or gastrointestinal tube (gastrointestinal perforation)
painful or altered digestion, which may include nausea, vomiting, stomach acid, abdominal distension, and stomach discomfort (chronic dyspepsia)
inflammation of the stomach lining (gastritis)
Warnings and precautions
If you notice signs of skin rash, red and painful skin around body openings (mucous membranes) or allergic reactions after taking Okidol, stop taking this medication and inform your doctor immediately.
If you notice any sign of bleeding in the stomach or intestines (e.g., bright red stools, black tarry stools, vomiting blood or dark particles that look like coffee grounds), stop taking this medication and inform your doctor immediately.
If you notice any sign of ulcers or perforation (symptoms may include: severe stomach pain, chills, nausea, vomiting, heartburn) after taking Okidol, stop taking this medication and inform your doctor immediately.
Elderly people may experience more side effects with NSAIDs, especially stomach and intestinal side effects, which can be fatal. If you are an elderly patient, the product should be used with caution.
Side effects can be minimized by taking lower doses for the shortest time necessary to relieve symptoms.
Anti-inflammatory/analgesic medications, such as ketoprofen, may be associated with a small increased risk of heart attack or stroke, especially when used in high doses and for prolonged periods. Do not exceed the recommended dose or treatment duration.
The use of Okidol with other products containing NSAIDs (e.g., ibuprofen, aspirin, celecoxib) should be avoided.
Stop taking this medication if you experience any vision problems, such as blurred vision.
Since Okidol is used to treat symptoms such as fever, it may mask a more serious underlying condition. If your symptoms persist, inform your doctor.
Taking a pain reliever to relieve headaches for a long time can worsen them.
Consult your doctor or pharmacist before starting to take Okidol:
Infections
Okidol may mask the signs of an infection, such as fever and pain. Consequently, Okidol may delay appropriate treatment of the infection, which may increase the risk of complications. This has been observed in bacterial pneumonia and bacterial skin infections related to chickenpox. If you take this medication while having an infection and the symptoms of the infection persist or worsen, consult a doctor without delay.
Children and adolescents
Okidol should not be administered to children under 18 years of age.
Taking Okidol with other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication. This includes medications without a prescription or herbal remedies.
You must inform your doctor or pharmacistif you are taking any of the following medications:
Taking Okidol with alcohol
Alcohol can cause irritation of the throat, stomach, and intestines, so there is a greater risk of bleeding and ulcers, and this risk increases when NSAIDs are taken at the same time.
Pregnancy and lactation
Do not take this medication if you are in the third trimester of pregnancy, as it may harm the fetus or cause problems during delivery. It may cause kidney and heart problems in the fetus. It may affect your or your child's predisposition to suffer from bleeding and prolong or delay delivery longer than expected. Ketoprofen should not be used during the first six months of pregnancy unless the clinical situation of the woman requires treatment with ketoprofen. If during this time or while you plan to become pregnant, you need treatment, the lowest dose should be used for the shortest possible time. If you take ketoprofen for a few days from week 20 of pregnancy onwards, it may cause kidney problems in the fetus, which may lead to a reduction in the volume of amniotic fluid surrounding it (oligohydramnios) or narrowing of the blood vessels (ductus arteriosus) of the fetal heart. If you need treatment for more than a few days, your doctor will recommend closer monitoring.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
If after taking Okidol you feel drowsy, dizzy, have blurred vision, or have convulsions, do not drive, use machinery, or perform activities that require a high level of alertness (see section 4 "Possible side effects").
Okidol contains glucose and sucrose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The lowest effective dose should be used for the shortest time necessary to relieve symptoms. If you have an infection, consult a doctor without delay if the symptoms (such as fever and pain) persist or worsen (see section 2).
The recommended dose is 1 sachet up to 3 times a day, as needed.
Wait at least 4 hours before taking another sachet.
Do not exceed the recommended dose.
If the symptoms persist or the pain worsens, or if new symptoms appear, consult your doctor or pharmacist.
Use in children
Okidol should not be taken by children under 18 years of age.
Use in elderly patients
Do not take more than 1 sachet of Okidol in 24 hours.
Method of administration
Okidol is for oral use.
The contents of the sachet can be placed directly on the tongue. You can take Okidol with or without water, as the granules will dissolve in your saliva.
If you take more Okidol than you should
If you accidentally take more Okidol than recommended, you may feel drowsy or nauseous. You should seek medical attention immediately, even if you feel well.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service. Telephone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Okidol
Do not take a double dose to make up for forgotten doses.
If you forget to take Okidol, take it as soon as possible. Do not take a double dose to make up for the forgotten dose, and make sure to leave a minimum of 4 hours between doses and do not exceed the maximum of 3 sachets per day.
If you stop taking Okidol
You should stop taking this medication as soon as you feel better.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Stop taking Okidol and seek medical attention immediatelyif at any time during treatment with Okidol you develop:
Inform your doctor if you experience:
The side effects of Okidol may include:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(frequency cannot be estimated from available data)
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medications: www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date stated on the packaging. The expiration date refers to the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of Okidol
Appearance of the Product and Packaging Content
The Okidol granules are white to ivory in color and are packaged in sachets.
The packages are available in 8, 10, 15, 16, or 20 sachets. Only some package sizes may be marketed.
Marketing Authorization Holder
Dompe farmaceutici S.P.A.
Via San Martino, 12
20122 – Milan
Italy
Manufacturer
Dompé farmaceutici S.p.A.
Via Campo di Pile
67100 L'Aquila
Italy
This medicinal product is authorized in the EEA Member States under the following names:
Bulgaria Okitask 25 mg granules
Croatia Okitask 25 mg coated granules in sachet
France Okitask 25 mg coated granules in sachet
Finland Okitask 25 mg granules
Greece Okitask 25 mg κόνις
Hungary Okitask 25 mg granulate
Latvia Okitask 25 mg coated granules in sachet
Lithuania Okitask 25 mg coated granules in sachet
Netherlands Okitask 25 mg coated granulate
Poland Okitask 25 mg coated granulate
Portugal Okiact 25 mg coated granulate in sachet
Romania Okitask 25 mg coated granules in sachet
Slovenia Okitask 25mg granules in sachet
Spain Okidol 25 mg granulate
Date of the last revision of this prospectus: February 2025